|
Cizzle Biotechnology Holdings PLC on Monday saw its shares surge as it reported that the process of preparing for submission of its CIZ1B test for Clinical Laboratory Improvement Amendments [CLIA] is nearing completion. The London-based life sciences company engaged in developing a blood test for the early detection of the different forms of lung cancer said its North American licencing partner Cizzle Bio Inc, known as BIO, is in the final stages of the CLIA accreditation process and expects to submit an application for approval in the second quarter of 2026. ‘Given the positive progress, BIO and the company have strengthened their commitment with a new payment schedule which includes a further minimum $3.5 million advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale,’ Cizzle Biotechnology said. Cizzle shares jumped 23% to 1.60 pence each on Monday afternoon in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
